Current Rating and Its Significance
On 12 March 2026, Venus Remedies Ltd’s rating was revised from 'Hold' to 'Buy' by MarketsMOJO, accompanied by a notable increase in its Mojo Score from 67 to 74. This elevated rating signals a positive outlook on the stock, suggesting that it currently offers attractive investment potential based on a comprehensive evaluation of its quality, valuation, financial trends, and technical indicators. For investors, a 'Buy' rating indicates confidence in the company’s ability to deliver favourable returns relative to its sector and market peers.
Here’s How Venus Remedies Ltd Looks Today
As of 04 April 2026, Venus Remedies Ltd demonstrates robust performance across multiple parameters. The company operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap stock. Despite its smaller market capitalisation, the stock has exhibited remarkable momentum, with a one-day gain of 4.96% and a one-month surge of 39.56%. Over the past year, the stock has delivered an impressive return of 191.73%, significantly outperforming broader market indices such as the BSE500.
Quality Assessment
The quality grade assigned to Venus Remedies Ltd is 'average', reflecting a stable operational foundation. The company maintains a low debt-to-equity ratio, effectively zero, which minimises financial risk and enhances balance sheet strength. Additionally, Venus Remedies has consistently reported positive quarterly results for five consecutive quarters, underscoring operational resilience and steady earnings growth. The latest quarterly profit after tax (PAT) stands at ₹25.58 crores, marking a substantial year-on-year increase of 116.9%. Return on Capital Employed (ROCE) is also noteworthy at 13.99%, indicating efficient utilisation of capital resources.
Valuation Perspective
Venus Remedies Ltd’s valuation is considered 'fair' with a Price to Book (P/B) ratio of 2. This suggests the stock is trading at a premium relative to its book value, which is justified by its strong earnings growth and market position. The company’s Return on Equity (ROE) is 10.5%, supporting the premium valuation. Investors should note that the stock’s Price/Earnings to Growth (PEG) ratio is an exceptionally low 0.1, signalling that the stock’s price growth is not only supported by earnings expansion but may also be undervalued relative to its growth prospects. This combination of metrics indicates that the stock is attractively priced for investors seeking growth at a reasonable valuation.
Financial Trend and Performance
The financial trend for Venus Remedies Ltd is rated as 'very positive'. The company has recorded a remarkable 96.37% growth in operating profit, reflecting strong operational leverage and effective cost management. Inventory turnover ratio is high at 6.58 times, indicating efficient inventory management and healthy sales velocity. Profit growth over the past year has been substantial at 182.3%, closely aligned with the stock’s price appreciation. This strong correlation between profit growth and stock returns reinforces the sustainability of the company’s upward trajectory.
Technical Outlook
From a technical standpoint, Venus Remedies Ltd is rated 'bullish'. The stock’s recent price action shows strong momentum, with gains of 18.38% year-to-date and nearly doubling over the past six months (99.82%). Institutional investors have increased their holdings by 0.67% in the previous quarter, now collectively owning 3.28% of the company. This growing institutional interest often reflects confidence in the company’s fundamentals and can provide additional support to the stock price. The bullish technical grade suggests that the stock’s price trend is likely to continue favourably in the near term.
Long-Term and Short-Term Returns
Venus Remedies Ltd has demonstrated market-beating performance over multiple time horizons. The stock’s 1-year return of 191.73% far exceeds the average returns of the BSE500 index. Additionally, the stock has outperformed the broader market over the last three years and three months, highlighting its consistent ability to generate superior returns. This performance is underpinned by strong earnings growth, prudent financial management, and positive market sentiment.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Implications for Investors
For investors evaluating Venus Remedies Ltd, the 'Buy' rating reflects a favourable risk-reward profile supported by solid fundamentals and positive market dynamics. The company’s low leverage, strong profit growth, and efficient capital utilisation provide a sound foundation for future expansion. While the valuation is at a premium, it is justified by the company’s growth trajectory and robust returns on equity and capital employed.
Moreover, the bullish technical outlook and increasing institutional participation add further confidence in the stock’s near-term prospects. Investors should consider the stock as a growth-oriented opportunity within the Pharmaceuticals & Biotechnology sector, with the potential to deliver sustained returns in line with its recent performance.
Summary
In summary, Venus Remedies Ltd’s current 'Buy' rating by MarketsMOJO, updated on 12 March 2026, is underpinned by a comprehensive assessment of quality, valuation, financial trends, and technical strength. As of 04 April 2026, the company exhibits strong earnings growth, efficient operations, and positive market sentiment, making it an attractive option for investors seeking exposure to a high-growth microcap within the pharmaceutical space.
Investors should continue to monitor quarterly results and market developments to ensure alignment with their investment objectives, but the current data supports a constructive outlook for Venus Remedies Ltd.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
